Gyros - Pharmacokinetics (PK), Toxicokinetics (TK), Pharmacodynamics (PD), ligand binding assay, kinetic profile, PK profiling assesment

Posters and presentations

Gyrolab in a GxP environment: the Merck Serono experience

C. Crosasso, E. Bertotti, V. Castagna, S. Riva and L. Colombo, 5^th Annual European Gyrolab Seminar, Siena, Italy, 2011

(PDF, 54.7 kB)

Download

High Throughput Ligand Binding Assay for Therapeutic Antibodies and Biomarkers Using Gyros Microfluidic Instrument

C. Mallozzi, M. Kavosi, Pfizer, Inaugural North American Gyrolab Seminar, Basking Ridge, 2010

(PDF, 853.0 kB)

Download

High Throughput Ligand Binding Assay for Therapeutic Antibodies and Biomarkers Using Gyros Microfluidic Instrument

H. Salimi-Moosavi, AAPS National Biotechnology Conference, San Francisco, 2010

(PDF, 354.0 kB)

Download

Publications and articles

Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized Pichia pastoris with specific glycoforms: A comparative study with CHO produced materials

L. Liua et al., Biologicals, Volume 39, Issue 4, Pages 205-210, July 2011

Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study

N. Zhang et al., mAbs 3:3, pages 289-298, May/June 2011

A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo

Y.G. Ni et al., J. Lipid Res. 2011 52:(1) 78-86.

Impact of methionine oxidation in human IgG1Fc on serum half-life of monoclonal antibodies

W. Wang et al., Molecular Immunology, online January 2011

Application of miniaturized immunoassays to discovery pharmacokinetic bioanalysis

J. Roman et al., Journal of Pharmacological and Toxicological Methods, online December 2010

Download your FREE OF CHARGE copy here. Courtesy of Gyros.

(PDF, 1.3 MB)

Download

Expansion and Activation Kinetics of Immune Cells during Early Phase of GVHD in Mouse Model Based on Chemotherapy Conditioning

B. Sadeghi et al., Clinical and Developmental Immunology, Volume 2010 (2010)

Application of the Gyrolab™ platform to ligand-binding assays: a user’s perspective

J. Mora et al., Bioanalysis, Volume 2, Issue 10, pages 1711-1715, October 2010

Download your FREE OF CHARGE copy here. Courtesy of Gyros.

An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males

K. Chad et al., British Journal of Pharmacology, Volume 69, Issue 6, pages 645-655, February 2010

New analytical technologies: Pharmaceutical applications to proteins and antibodies - An industry perspective

L. Colombo et al., National meeting on medicinal chemistry (NMMC), Abano Terme, Italy, Book of abstracts, p39-40, October 2010

Phase I, Double-blind, Randomized, Placebo-controlled, Dose-escalation Study of NI-0401 (a Fully Human Anti-CD3 Monoclonal Antibody) in Patients with Moderate to Severe Active Crohn's Disease

C. Janneke van der Woude et al., Inflammatory Bowel Disease, January 2010

A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma

D. Singh et al., BMC Pulmonary Medicine 2010, 10:3

Minimising Volume, Maximising Returns

S. Hannam, J. Allinson and R. Briggs, European Pharmaceutical Review, Discovery Technology, Spring 2010